Commercialisation of University Peptide Synthesis Technology via Executive Management for Spin-Out Company Pepmotec

About

Newcastle University awarded a contract to Dr Cliff Rush for the commercialisation of university research through the provision of management skills to assist in successful spin-out company creation.

The contract supported the formation of Pepmotec, a company established to exploit a novel chemical synthesis pathway developed by Dr Steven Cobb of Durham University that overcomes limitations in producing modified and cyclic therapeutic peptides.

The technology is protected by two related patent families and has potential for drug discovery and re-engineering of therapeutic peptides.

The executive was tasked with reviewing business aims, producing a viable business plan, acting for the company during legal formation and post-formation matters, and securing venture capital or customer-funded work.

The contract value was AUD 25,000.